Apogee Therapeutics

Two businessmen pushing giant puzzle pieces together as the sun sets behind them
Biotech

AbbVie inks $10.9B Apogee buyout to bag eczema prospect

The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.
Nick Paul Taylor Jun 22, 2026 7:59am
Money present

Apogee bags $1.3B royalty funding deal to advance eczema hopeful

May 27, 2026 8:57am
target reach ladder climb meet win beat competition

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Mar 23, 2026 9:00am
eczema atopic dermatitis Black African American patient skin of color

Apogee claims IL-13 antibody sets new eczema treatment standard

Jul 7, 2025 8:29am
parachute chutes and ladders

Sanofi finds new R&D head—Chutes & Ladders

Sep 1, 2023 9:30am
Wall Street stock exchange finance shares share price Nasdaq

Apogee, Sagimet overshoot IPO expectations as they reach Nasdaq

Jul 14, 2023 8:55am